Loading
PS
Pacific Shuanglin Bio-pharmacy Co., Ltd. Stock: price and insider trades · China
派林生物
No insider purchase over the last 90 days. The latest, by 司文彬, was filed 20 May 2026.
Pacific Shuanglin Bio-pharmacy Co., Ltd.: what insiders have been doing
Pacific Shuanglin Bio-pharmacy Co., Ltd. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). 1 insider has disclosed 2 filings since 26 October 2025.
Only purchases show up on the open market, 2 purchases in all worth €14k, filed by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 board member among the declarants. 司文彬 filed the largest purchase, €8,092, on 20 May 2026.
The latest purchase dates back some time: it was published 159 days ago, on 20 May 2026.
With 2 filings in twelve months, the company is in line with the median of 2 filings across the 533 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 17 purchases and 6 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€545,445
17 ops. · all time
Sell Volume
€16M
6 ops. · all time
Who traded when
BuySale荣先奎3 buys
郭麾3 buys
叶兰2 buys
司文彬2 buys
赵玉林2 buys
Since the insiders bought
- -16.1%Entry CN¥11.55 · Close 14 Oct 2026 CN¥9.69
- -43.8%Entry CN¥21.69 · Close at T+365 CN¥12.20
- -43.8%Entry CN¥21.69 · Close at T+365 CN¥12.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,804 of 26,330 companies
50.1
score / 100
Value39
Quality61
FCF yld-6.0%
Earn yld4.5%
EV/EBITDA15.2x
ROE3.4%
Gross mgn42%
Net mgn16%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥10.41
Analyst consensus
1 analystsCN¥25.50Target CN¥25.50(+145%)CN¥25.50
Income statement
RevenueCN¥2.6B
Gross profitCN¥1.1B42% margin
EBITDACN¥660.6M25% margin
Net incomeCN¥419.3M10.8% margin
Valuation
PER (trailing)37.2x
P/Book0.9x
Beta0.45
Balance sheet & cash
Market capCN¥9.9B
Total debtCN¥813.1M
Free Cash Flow-CN¥549.4M
Debt / Equity15%
Profitability & ownership
ROE3.4%
ROA2.6%
% insiders44.6%
% institutions6.4%
Last declaration on 20 May 2026
Declarations23 total
6,000 shares59.8% of flowA股XSHESZSE:273000000639571100
Canonical exit: 18 Aug 2026 (T+90)
4,000 shares40.2% of flowA股XSHESZSE:273000000635414240
Canonical exit: 17 Aug 2026 (T+90)
5,000 shares23.9% of flowA股XSHESZSE:173000008868500400
Canonical exit: 24 Jul 2025 (T+90)
7,500 shares48.9% of flowA股XSHESZSE:173000008868500580
Canonical exit: 24 Jul 2025 (T+90)
200 shares8.9% of flowA股XSHESZSE:173000008717793300
Canonical exit: 25 May 2025 (T+90)
2,000 shares91.1% of flowA股XSHESZSE:173000008552387420
Canonical exit: 14 May 2025 (T+90)
1,500 shares35.6% of flowA股XSHESZSE:173000008451201340
Canonical exit: 14 Apr 2025 (T+90)
800 shares18.0% of flowA股XSHESZSE:173000008409120800
Canonical exit: 7 Apr 2025 (T+90)
10,000 shares50.4% of flowA股XSHESZSE:173000008405393340
Canonical exit: 6 Apr 2025 (T+90)
2,000 shares13.8% of flowA股XSHESZSE:173000008405393300
Canonical exit: 6 Apr 2025 (T+90)
5,000 shares25.8% of flowA股XSHESZSE:173000008396452540
Canonical exit: 2 Apr 2025 (T+90)
2,000 shares46.4% of flowA股XSHESZSE:173000008396452580
Canonical exit: 2 Apr 2025 (T+90)
3,500,000 shares62.1% of flowA股XSHESZSE:173000006682573300
32,600 shares100.0% of flowA股XSHESZSE:173000006618752160
41,000 shares16.8% of flowA股XSHESZSE:173000006397250720
59,000 shares24.9% of flowA股XSHESZSE:173000006385524860
32,000 shares13.1% of flowA股XSHESZSE:173000006379791870
2,000,000 shares37.9% of flowA股XSHESZSE:173000006130764540
2,800 shares48.2% of flowA股XSHESZSE:173000005355032420
Canonical exit: 13 Dec 2021 (T+90)
11,000 shares100.0% of flowA股XSHESZSE:173000004832742720
Canonical exit: 13 Dec 2021 (T+90)
100,000 shares45.2% of flowA股XSHESZSE:173000005677879260
Canonical exit: 13 Dec 2021 (T+90)
4,000 shares37.3% of flowA股XSHESZSE:173000004826249340
Canonical exit: 9 Dec 2021 (T+90)
2,800 shares51.8% of flowA股XSHESZSE:173000004818779260
Canonical exit: 9 Dec 2021 (T+90)
23 of 23 declarations
About Pacific Shuanglin Bio-pharmacy Co., Ltd.
派林生物 is a company focused on the health and pharmaceutical sector. It is listed on the XSHE market.
